<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007058</url>
  </required_header>
  <id_info>
    <org_study_id>LAB05-0326</org_study_id>
    <nct_id>NCT01007058</nct_id>
  </id_info>
  <brief_title>Markers of Response to Intravesical Bladder Cancer Therapy</brief_title>
  <official_title>Markers of Response to Intravesical Bladder Cancer Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Flight Attendant Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this laboratory research study is to see if researchers can predict whose cancer
      will stay in remission and whose will return in patients receiving treatment for bladder
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, researchers are looking at markers that they could use to identify - at an
      early time point - those patients who might not respond to this treatment. This would allow
      researchers to provide future patients with information about their chances of responding to
      such treatment. And, with this information, researchers could better counsel those patients
      who might benefit from a different therapy at an earlier time point.

      Treatment with BCG or BCG plus interferon is currently the most effective nonsurgical
      treatment for superficial bladder cancer. However, at this time, there is no reliable test
      that can help researchers predict which patients will respond to this therapy. You will be
      receiving BCG or BCG plus interferon therapy as planned by your physician. This is a standard
      therapy that will be decided by your doctor and based on your disease characteristics. If you
      agree to take part in this study, your participation will not affect the treatment you will
      receive in any way. Your follow-up and disease monitoring will be done according to standard
      routines.

      By participating in this study, you agree to provide researchers with 4 tablespoons (or as
      much as you can produce) of urine at the following time points.

        1. Before you start therapy.

        2. Just before and 4 hours after your last treatment (which usually occurs 6 weeks after
           start of treatment).

        3. Just before and 4 hours after your last treatment of the second course of therapy (which
           is usually about 3 months after the beginning of the first course of therapy.

      In addition, you will provide researchers with a bladder wash sample. This sample will be
      collected during routine catheterization (for your planned treatment) or during your routine
      cystoscopic exam. Bladder wash samples will be collected at the following time points.

        1. Before you start therapy.

        2. Just before your last treatment (which usually occurs 6 weeks after start of treatment).

        3. At your first routine cystoscopic follow-up (which usually occurs at 3 months).

        4. At your second routine cystoscopic follow-up (which usually occurs at 6 months).

      Your follow-up cystoscopies and maintenance therapy will be done according to routine care as
      decided by your doctor and are not affected by your participation in this study. You will be
      part of the study for about 24 months after beginning the treatments. At the end of that
      period, between 23 and 27 months, you will be checked with cystoscopy and cytology to see if
      the tumor has come back, as part of standard of care.

      In addition, information will be collected from your medical chart about other medications
      that you are taking and other conditions, such as diabetes or heart disease, that you may
      have. Information will also be collected about previous treatment that you have had for
      bladder cancer as well as other treatments that you may receive during this study. This may
      include treatments that are received at an outside health facility. Neither your name nor
      your medical record number will be kept with this information. All of the information
      collected for this study will be kept in a locked cabinet to which only the researchers have
      access. Upon completion of the study, the information sheets will be destroyed.

      This is an investigational study.

      A total of 300 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Clinical tumor recurrence or progression by 24 months after initiation of intravesical immunotherapy</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Response Markers</arm_group_label>
    <description>Urine Collection and Bladder wash of Bladder Cancer Patients with Treatment of BCG or BCG plus interferon</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4 tablespoons of urine and a bladder wash sample during catheterization (for planned
      treatment) or during routine cystoscopic exam, both samples at 4 different time points
      before, during and after therapy courses.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Bladder cancer patients, 18 years or older, who will be receiving treatment with BCG or BCG
        + Interferon at UT MD Anderson Cancer Center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease Characteristics:

          -  Histologically confirmed primary or recurrent non-muscle-invasive transitional cell
             carcinoma with an intact bladder

          -  Stage Ta, T1, or carcinoma in situ

          -  Grade 1, 2, or 3

          -  Primary disease site must be the urinary bladder

          -  No evidence of tumor invasion of the muscularis propria by cystoscopy and biopsy
             within the past 6 weeks

          -  Upper tract imaging within the prior 12 months

        Patient Characteristics:

          -  Age: 18 years and above

          -  Gender: Male or female

          -  Life expectancy: 24 months or greater

          -  Performance status: 0 - 1

        Prior Therapy:

          -  Biologic therapy: allowed

          -  Chemotherapy: allowed

          -  Radiotherapy: no prior pelvic radiotherapy

          -  Surgery: recovered from prior transurethral resection

        Intravesical Immunotherapy:

          -  In the opinion of the treating physician, the patient must be a candidate for
             &quot;standard of care&quot; intravesical immunotherapy, defined as

               -  Induction with 6 weekly treatments of intravesical BCG followed by maintenance
                  with 3 weekly treatments of intravesical BCG at 3 months. Continued maintenance
                  therapy at 6 months and then every 6 months for total of 36 months (&quot;Lamm
                  regimen&quot;) (38) is optional and left to the discretion of the physician or

               -  Induction with 6 weekly treatments of intravesical BCG plus IFN-alfa-2b followed
                  by maintenance with 3 weekly treatments of BCG plus IFN-alfa-2b at 3 months.
                  Continued maintenance therapy at 9 months, and 15 months (&quot;O'Donnell regimen&quot;)
                  (39) is optional and left to the discretion of the physician.

          -  Patients will be included in the study based on 'intent to treat'. If, after start of
             induction, the treating physician decides to alter the treatment regimen, patients
             will still be included for analysis.

        Special Situations:

        A special situation arises when during the course of the study, a patient develops
        recurrent tumor, and is deemed by the treating physician to require either a reinduction
        course of BCG therapy or therapy with BCG plus Interferon. In that case, the patient will
        remain in the protocol and, since urine cytology/FISH and cytokine responses are dependent
        on the treatment time-table, we will start collecting urine samples all over again, as
        already described previously in the protocol. Also, starting from the change in the
        treatment plan, the patient's overall time in the protocol will be prolonged up to the
        completion of a 24-month period of time.

        Exclusion Criteria

          -  Ongoing Pregnancy

          -  Patients who are not eligible to receive standard-of-care intravesical immunotherapy
             such as

               -  histologically confirmed pure squamous cell carcinoma or pure adenocarcinoma,

               -  patients with nonurothelial bladder cancer such as sarcoma, and immunocompromised
                  patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashish M. Kamat, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2009</study_first_submitted>
  <study_first_submitted_qc>November 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2009</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Bladder</keyword>
  <keyword>Non-muscle-invasive transitional cell carcinoma</keyword>
  <keyword>Intact bladder</keyword>
  <keyword>Intravesical Bladder Cancer Therapy</keyword>
  <keyword>Tumor Recurrence</keyword>
  <keyword>Surrogate markers of response</keyword>
  <keyword>BCG</keyword>
  <keyword>Bacillus Calmette Gu√©rin</keyword>
  <keyword>Interferon-alfa-2b</keyword>
  <keyword>IFN-alfa-2b</keyword>
  <keyword>Interferon</keyword>
  <keyword>Fluorescence in situ hybridization</keyword>
  <keyword>FISH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

